Sulphasalazine-induced agranulocytosis successfully treated with filgrastim.
Crawford
G P
GP
Laurence
B L
BL
D000293:Adolescent; D000380:Agranulocytosis / Q000139:chemically induced* / Q000188:drug therapy*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D012460:Sulfasalazine / Q000009:adverse effects*
D000893:Anti-Inflammatory Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D012460:Sulfasalazine; D000069585:Filgrastim